stocks logo

PROC

Procaps Group SA
$
1.010
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
High
1.010
Open
1.010
VWAP
--
Vol
--
Mkt Cap
283.19M
Low
1.010
Amount
--
EV/EBITDA(TTM)
7.36
Total Shares
112.82M
EV
377.11M
EV/OCF(TTM)
9.82
P/S(TTM)
0.24
Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
FY2023Q3
110.60M
+8.97%
0.090
-62.58%
110.40M
-0%
0.050
-83.66%
Estimates Revision
0 Analyst Rating
down Image
Wall Street analysts forecast PROC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROC is USD with a low forecast of USD and a high forecast of  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
down Image
Current: 1.010
sliders
Low
Averages
High
No Data

Valuation Metrics

The current forward P/E ratio for Procaps Group SA (PROC.O) is 2.49, compared to its 5-year average forward P/E of 39.68. For a more detailed relative valuation and DCF analysis to assess Procaps Group SA 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
39.68
Current PE
2.49
Overvalued PE
99.72
Undervalued PE
-20.36

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
7.03
Current EV/EBITDA
3.56
Overvalued EV/EBITDA
10.41
Undervalued EV/EBITDA
3.64

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
1.07
Current PS
0.25
Overvalued PS
1.80
Undervalued PS
0.33

Financials

Annual
Quarterly
FY2023Q3
YoY :
+7.25%
118.41M
Total Revenue
FY2023Q3
YoY :
-23.99%
13.18M
Operating Profit
FY2023Q3
YoY :
-63.69%
8.20M
Net Income after Tax
FY2023Q3
YoY :
-63.64%
0.08
EPS - Diluted
FY2023Q3
YoY :
-1074.31%
30.16M
Free Cash Flow
FY2023Q3
YoY :
-5.59%
57.77
Gross Profit Margin - %
FY2023Q3
2.29
FCF Margin - %
FY2023Q3
YoY :
-66.16%
6.92
Net Margin - %
FY2023Q3
28.75
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PROC News & Events

Events Timeline

2025-01-03 (ET)
2025-01-03
15:22:47
Procaps Group receives additional delinquency letter
select
2024-11-15 (ET)
2024-11-15
17:20:44
Procaps Group receives Nasdaq listing determination, will request hearing
select
2024-10-10 (ET)
2024-10-10
17:33:15
Procaps Group CEO issues letter to shareholders amid independent investigation
select
Sign Up For More Events

News

7.0
02-03Business Insider
Procaps Group receives delisting notice from Nasdaq
7.0
01-03Newsfilter
Procaps Group Receives Additional Delinquency Letter
7.0
01-03Business Insider
Procaps Group Faces Additional Nasdaq Delinquency Notice
Sign Up For More News

FAQ

arrow icon

What is Procaps Group SA (PROC) stock price today?

The current price of PROC is 1.01 USD — it has increased 0 % in the last trading day.

arrow icon

What is Procaps Group SA (PROC)'s business?

arrow icon

What is the price predicton of PROC Stock?

arrow icon

What is Procaps Group SA (PROC)'s revenue for the last quarter?

arrow icon

What is Procaps Group SA (PROC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Procaps Group SA (PROC)'s fundamentals?

arrow icon

How many employees does Procaps Group SA (PROC). have?

arrow icon

What is Procaps Group SA (PROC) market cap?